drugset / Trial / NCT01512797
Treatment of Diabetes After Gastric Bypass With Sitagliptin
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
Timeline
- Start
- 2012-07
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |